Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer
Sabine Schmid(University of Bern), Geoffrey Liu(Princess Margaret Cancer Centre), Roula Raptis, Khaleeq Khan(Princess Margaret Cancer Centre), M. Catherine Brown(University Health Network), Katrina Hueniken(Centre for Addiction and Mental Health), Adrian G. Sacher(Princess Margaret Cancer Centre), Luna Jia Zhan(University Health Network), Frances A. Shepherd(University Health Network), Benjamin Grant(University Health Network), Simren Chotai(University Health Network), Wei Xu(University Health Network), Patrick M. Moriarty(Takeda (Canada)), Sierra Cheng(Princess Margaret Cancer Centre), Karmugi Balaratnam(Princess Margaret Cancer Centre), Devalben Patel(University Health Network), Miguel García-Pardo(Hospital Universitario Ramón y Cajal), Penelope A. Bradbury(University Health Network), Natasha B. Leighl(Princess Margaret Cancer Centre)
Cited by 23
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k